Ambit Biosciences (San Diego, CA) a clinical-stage biopharmaceutical company focused on kinase inhibitors for the treatment of cancer and other conditions, closed a $30M Series D financing. Participants include Apposite Capital, Perseus-Soros Biopharmaceutical Fund, OrbiMed, Forward Ventures, Roche Venture Fund, MedImmune Ventures, Gimv, GrowthWorks, GeneChem, Radius Ventures and NovaQuest Capital Management.

The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science professionals on-line and in-print. Contact arubenstein@rnaventures.com for details.